Plain-English translation of NCT06195228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a real-world study that follows patients with advanced thyroid cancer who are receiving targeted therapy—treatments designed to attack specific genetic changes in their cancer cells. Researchers will collect information about patients' genetic test results and track how well different targeted treatments work for different types of advanced thyroid cancer. The goal is to understand which genetic markers predict which treatments work best, so future patients can be matched with the most effective therapy from the start.
Advanced thyroid cancer is difficult to treat, especially when it no longer responds to radioactive iodine or cannot be surgically removed. By studying how genetic testing of tumors can guide treatment choices, this study hopes to help doctors personalize therapy and improve outcomes for patients facing these aggressive forms of the disease.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to review your medical records, pathology reports, and genetic test results from your thyroid cancer. The study collects information both from the past (retrospective data) and going forward (prospective monitoring), so you may be followed over time as you receive your targeted therapy. Researchers will track which treatments you receive, how well they work, and any side effects you experience—using this real-world information to understand how genetic markers guide successful treatment choices.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China